-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rivastigmine in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rivastigmine in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rivastigmine in Dementia Associated With Alzheimer's Disease Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Timbetasin Acetate in Keratitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Timbetasin Acetate in Keratitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Timbetasin Acetate in Keratitis Drug Details: Timbetasin acetate (RGN-259) is under development...
-
Product Insights
Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis Sicca (Dry Eye) - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Keratoconjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-9550 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AZD-9550 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AZD-9550 in Non-Alcoholic Steatohepatitis (NASH) Drug Details: AZD-9550 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Timbetasin Acetate in Keratoconjunctivitis Sicca (Dry Eye)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Timbetasin Acetate in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Timbetasin acetate (RGN-259) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LACTIN-V in Premature Labor (Tocolysis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LACTIN-V in Premature Labor (Tocolysis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LACTIN-V in Premature Labor (Tocolysis) Drug Details:LACTIN-V is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – timbetasin acetate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry timbetasin acetate Drug Details Timbetasin acetate (RGN-259) is under development for the treatment of...
-
Product Insights
Keratitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Keratitis is an inflammation of the cornea. Symptoms include eye redness, eye pain, blurred vision, decreased vision, and sensitivity to light. The Keratitis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Keratitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news...
-
Sector Analysis
Dry Eye Syndrome – Global Drug Forecast and Market Analysis to 2028
• Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade. However, the current treatment landscape is anticipated to witness a dramatic progress with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant...